DA

Daniel J Anderson

Chief Scientific Officer at Eikon Therapeutics

Daniel J Anderson has a diverse work experience spanning over two decades. Daniel J is currently serving as the Chief Scientific Officer at Eikon Therapeutics since December 2020. Prior to this, they held the position of Senior Vice President, Biology at Eikon Therapeutics from October 2019 to December 2020.

Before joining Eikon Therapeutics, Daniel worked at Recursion Pharmaceuticals as the Vice President, Biology from July 2018 to September 2019. Daniel J also served as the Senior Director, Biology at Recursion Pharmaceuticals from August 2017 to July 2018.

Daniel has a solid background in biology, having worked as the Director of Biology at Cleave Biosciences, Inc. from March 2012 to July 2017. Prior to that, they were a Senior Research Associate at Genentech from January 2009 to January 2012.

During their early career, Daniel gained research experience at esteemed institutions such as the Salk Institute, where they worked as a Graduate Student Researcher from May 2005 to January 2009. Daniel J conducted research on nuclear envelope and nuclear pore complex dynamics under the guidance of Martin Hetzer. Before that, they worked as a Researcher at the University of Pittsburgh from September 2000 to May 2004, focusing on biophysical and biochemical research on microtubule-based molecular motors under the supervision of Susan Gilbert. Daniel J also briefly worked as a Researcher at the University of Pennsylvania from June 1999 to August 2000.

Overall, Daniel's work experience showcases their expertise in biology and their progressive growth in leadership roles within the biotechnology industry.

Daniel J Anderson earned their Bachelor of Science degree in Biology from the University of Pittsburgh from 2000 to 2004. Daniel J then pursued a PhD in Cell Biology / Microscopy at UC San Diego and completed it from 2004 to 2008.

Links

Timeline

  • Chief Scientific Officer

    December, 2020 - present

  • Senior Vice President Biology

    October, 2019

View in org chart